OBJECTIVES: To evaluate survival after detection of recurrent cervical cancer by FDG-PET in symptomatic versus asymptomatic patients. METHODS: This is a prospective registry study of 103 patients treated with definitive chemoradiation for advanced cervical cancer who demonstrated no abnormal FDG uptake (a complete metabolic response, CMR) on their 3-month posttherapy FDG-PET. Their median age was 48 years (range 26-84). The clinical stages were Ib in 38, IIa in 1, IIb in 39, and IIIb in 25. All patients underwent subsequent surveillance FDG-PET. Patients were grouped according to symptom status at the time of the surveillance FDG-PET. Recurrence sites and survival data were analyzed. RESULTS: The median time from the 3-month posttherapy FDG-PET to the first surveillance FDG-PET was 13 months. 25 patients (25/103; 24%) were symptomatic at the time of surveillance FDG-PET and 21 of these had FDG-PET findings indicative of recurrence. 78 patients (78/103; 76%) were asymptomatic and 9 of these had tumor recurrence detected by PET. All recurrences were confirmed by biopsy or radiologic progression. The recurrences in the 21 symptomatic patients were loco regional in 4 and distant in 17. The 9 asymptomatic patients had isolated loco regional disease in 8 and distant disease in 1. All patients received treatment for recurrence. The three-year cause-specific survival for symptomatic recurrences was 19% versus 59% for asymptomatic recurrences (p=0.09). CONCLUSIONS: Surveillance FDG-PET can detect asymptomatic recurrent disease that is potentially amenable to salvage therapy. Prospective investigation of surveillance PET is warranted.
OBJECTIVES: To evaluate survival after detection of recurrent cervical cancer by FDG-PET in symptomatic versus asymptomatic patients. METHODS: This is a prospective registry study of 103 patients treated with definitive chemoradiation for advanced cervical cancer who demonstrated no abnormal FDG uptake (a complete metabolic response, CMR) on their 3-month posttherapy FDG-PET. Their median age was 48 years (range 26-84). The clinical stages were Ib in 38, IIa in 1, IIb in 39, and IIIb in 25. All patients underwent subsequent surveillance FDG-PET. Patients were grouped according to symptom status at the time of the surveillance FDG-PET. Recurrence sites and survival data were analyzed. RESULTS: The median time from the 3-month posttherapy FDG-PET to the first surveillance FDG-PET was 13 months. 25 patients (25/103; 24%) were symptomatic at the time of surveillance FDG-PET and 21 of these had FDG-PET findings indicative of recurrence. 78 patients (78/103; 76%) were asymptomatic and 9 of these had tumor recurrence detected by PET. All recurrences were confirmed by biopsy or radiologic progression. The recurrences in the 21 symptomatic patients were loco regional in 4 and distant in 17. The 9 asymptomatic patients had isolated loco regional disease in 8 and distant disease in 1. All patients received treatment for recurrence. The three-year cause-specific survival for symptomatic recurrences was 19% versus 59% for asymptomatic recurrences (p=0.09). CONCLUSIONS: Surveillance FDG-PET can detect asymptomatic recurrent disease that is potentially amenable to salvage therapy. Prospective investigation of surveillance PET is warranted.
Authors: Jason D Wright; Farrokh Dehdashti; Thomas J Herzog; David G Mutch; Phyllis C Huettner; Janet S Rader; Randall K Gibb; Matthew A Powell; Feng Gao; Barry A Siegel; Perry W Grigsby Journal: Cancer Date: 2005-12-01 Impact factor: 6.860
Authors: D Bodurka-Bevers; M Morris; P J Eifel; C Levenback; M W Bevers; K R Lucas; J T Wharton Journal: Gynecol Oncol Date: 2000-08 Impact factor: 5.482
Authors: P Morice; C Deyrolle; A Rey; D Atallah; P Pautier; S Camatte; A Thoury; C Lhomme; C Haie-Meder; D Castaigne Journal: Ann Oncol Date: 2004-02 Impact factor: 32.976
Authors: P Zola; L Fuso; S Mazzola; E Piovano; S Perotto; A Gadducci; L Galletto; F Landoni; T Maggino; F Raspagliesi; E Sartori; G Scambia Journal: Gynecol Oncol Date: 2007-09-14 Impact factor: 5.482
Authors: Karsten Beiderwellen; Johannes Grueneisen; Verena Ruhlmann; Paul Buderath; Bahriye Aktas; Philipp Heusch; Oliver Kraff; Michael Forsting; Thomas C Lauenstein; Lale Umutlu Journal: Eur J Nucl Med Mol Imaging Date: 2014-09-16 Impact factor: 9.236